NEW YORK, June 22 /PRNewswire-FirstCall/ -- Pfizer Inc said today it is returning to Neurocrine Biosciences, Inc. the development and marketing rights for Indiplon, a medicine in development to treat insomnia. This includes both the collaboration to develop and co-market Indiplon in the U.S. as well as Pfizer's exclusive license to develop and market Indiplon outside of the U.S.
immediately via Wieck Photo Database to any media with telephoto receiver
or electronic darkroom, PC or Macintosh, that can accept overhead
transmissions. To retrieve a logo, please call 972-392-0888.
